Literature DB >> 29541253

Toll-like receptor 9 activation by CpG oligodeoxynucleotide 7909 enhances the radiosensitivity of A549 lung cancer cells via the p53 signaling pathway.

Sujuan Yuan1, Tiankui Qiao1, Xuan Li1, Xibing Zhuang1, Wei Chen1, Xue Chen2, Qi Zhang1.   

Abstract

Unmethylated cytosine-phosphorothioate-guanine (CpG)-containing oligodeoxynucleotides (ODNs) are synthetic DNA sequences that mimic bacterial DNA, and are known to serve as ligands for Toll-like receptor 9 (TLR9). The interaction between a CpG ODNs with TLR9 activates the complex downstream cascade that contributes to exerting its function. In the present study, the results of clonogenic assays demonstrated that the activation of TLR9 by CpG ODNs significantly increased the radiosensitivity of A549 lung cancer cells, with a sensitivity enhancement ratio (SER) of 1.28. When the expression of TLR9 was effectively silenced, CpG ODNs used alone were identified to produce SERs as low as 1.01. Flow cytometry demonstrated that the interaction between TLR9 and CpG ODN 7909 alone did not significantly affect the rate of apoptosis, but may significantly enhance the radiation-induced apoptosis of A549 cells. Western blot analysis revealed that TLR9 activation by CpG ODN 7909 increased the levels of mitogen-activated protein kinase 14, cellular tumor antigen p53, B-cell lymphoma 2 associated X protein and genome polyprotein, and decreased Bcl-2 expression levels, whereas these effects were not observed in CpG ODN 7909-treated cells in which TLR9 was knocked down. These results suggest that CpG ODN 7909 may enhance radiosensitivity through TLR9 activation, and partially via the p53 pathway in A549 lung cancer cells.

Entities:  

Keywords:  CpG oligodeoxynucleotide 7909; Toll-like receptors; apoptosis; irradiation; lung cancer; radiosensitizer; signal transduction

Year:  2018        PMID: 29541253      PMCID: PMC5835961          DOI: 10.3892/ol.2018.7916

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  40 in total

1.  Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9.

Authors:  Hui Wang; Elizabeth R Rayburn; Wei Wang; Ekambar R Kandimalla; Sudhir Agrawal; Ruiwen Zhang
Journal:  Mol Cancer Ther       Date:  2006-06       Impact factor: 6.261

Review 2.  TLR9 agonists: immune mechanisms and therapeutic potential in domestic animals.

Authors:  George Mutwiri
Journal:  Vet Immunol Immunopathol       Date:  2011-06-06       Impact factor: 2.046

3.  Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c.

Authors:  T Rossé; R Olivier; L Monney; M Rager; S Conus; I Fellay; B Jansen; C Borner
Journal:  Nature       Date:  1998-01-29       Impact factor: 49.962

Review 4.  Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases.

Authors:  Gary L Johnson; Razvan Lapadat
Journal:  Science       Date:  2002-12-06       Impact factor: 47.728

5.  Effects of CPG ODN on biological behavior of PANC-1 and expression of TLR9 in pancreatic cancer.

Authors:  Han-Qing Wu; Bo Wang; Shi-Kai Zhu; Yuan Tian; Jing-Hui Zhang; He-Shui Wu
Journal:  World J Gastroenterol       Date:  2011-02-28       Impact factor: 5.742

Review 6.  Toll-like receptor 9 agonists as cancer therapeutics.

Authors:  Udo Holtick; Max E Scheulen; Michael S von Bergwelt-Baildon; Martin R Weihrauch
Journal:  Expert Opin Investig Drugs       Date:  2011-01-22       Impact factor: 6.206

7.  Design, synthesis and biological evaluation of 1, 4-dihydro indeno[1,2-c] pyrazole linked oxindole analogues as potential anticancer agents targeting tubulin and inducing p53 dependent apoptosis.

Authors:  Irfan Khan; Koteswara Rao Garikapati; Anver Basha Shaik; Venkata Krishna Kanth Makani; Abdul Rahim; Mohd Adil Shareef; V Ganga Reddy; Manika Pal-Bhadra; Ahmed Kamal; C Ganesh Kumar
Journal:  Eur J Med Chem       Date:  2017-12-05       Impact factor: 6.514

8.  Humanin peptide suppresses apoptosis by interfering with Bax activation.

Authors:  Bin Guo; Dayong Zhai; Edelmira Cabezas; Kate Welsh; Shahrzad Nouraini; Arnold C Satterthwait; John C Reed
Journal:  Nature       Date:  2003-05-04       Impact factor: 49.962

9.  Accumulation of wild-type p53 protein upon gamma-irradiation induces a G2 arrest-dependent immunoglobulin kappa light chain gene expression.

Authors:  R Aloni-Grinstein; D Schwartz; V Rotter
Journal:  EMBO J       Date:  1995-04-03       Impact factor: 11.598

10.  Cisplatin induces HepG2 cell cycle arrest through targeting specific long noncoding RNAs and the p53 signaling pathway.

Authors:  Ping Wang; Jiayue Cui; Jihong Wen; Yunhui Guo; Liangzi Zhang; Xia Chen
Journal:  Oncol Lett       Date:  2016-10-18       Impact factor: 2.967

View more
  4 in total

1.  Comparison of tumor related signaling pathways with known compounds to determine potential agents for lung adenocarcinoma.

Authors:  Song Xu; Renwang Liu; Yurong Da
Journal:  Thorac Cancer       Date:  2018-06-05       Impact factor: 3.500

2.  The Biocomplex Assembled from Antigen Peptide and Toll-like Receptor Agonist Improved the Immunity against Pancreatic Adenocarcinoma In Vivo.

Authors:  Wenming Feng; Hongbin Yu; Tao Xue; Chunyong Wu; Fan Ren; Ge Cui
Journal:  J Oncol       Date:  2022-08-25       Impact factor: 4.501

Review 3.  Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy.

Authors:  Yi Wang; Kai Conrad Cecil Johnson; Margaret E Gatti-Mays; Zihai Li
Journal:  J Hematol Oncol       Date:  2022-08-28       Impact factor: 23.168

Review 4.  CpG Oligodeoxynucleotides for Anticancer Monotherapy from Preclinical Stages to Clinical Trials.

Authors:  Zhongkun Zhang; Jimmy Chun-Tien Kuo; Siyu Yao; Chi Zhang; Hira Khan; Robert J Lee
Journal:  Pharmaceutics       Date:  2021-12-28       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.